# A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

> **NCT05844228** · PHASE1 · COMPLETED · sponsor: **Vir Biotechnology, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** VIR-2218

## Key facts

- **NCT ID:** NCT05844228
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-04-21
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05844228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05844228, "A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05844228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*